Cannabidiol (CBD) is an abundant non‐psychoactive phytocannabinoid in cannabis
extracts which has high affinity on a series of receptors, including Type 1 cannabinoid …

Anxiety disorders are the most prevalent psychiatric disorders and a leading cause of
disability. While there continues to be expansive research in posttraumatic stress disorder …

Background Medicinal cannabinoids, including medicinal cannabis and pharmaceutical
cannabinoids and their synthetic derivatives, such as tetrahydrocannabinol (THC) and …

Rationale Cannabidiol (CBD) products lacking regulatory approval are being used to self-
treat a myriad of conditions and for their unsubstantiated health benefits. The scientific …

Background: Cannabidiol is being pursued as a therapeutic treatment for multiple
conditions, usually by oral delivery. Animal studies suggest oral bioavailability is low, but …

Background Public and medical interest in cannabidiol (CBD) has been rising, and CBD is
now available from various sources. Research into the effects of low-dose CBD on outcomes …

Objective: Research in both animals and humans indicates that cannabidiol (CBD) has
antipsychotic properties. The authors assessed the safety and effectiveness of CBD in …

The potential therapeutic use of some Cannabis sativa plant compounds has been attracting
great interest, especially for managing neuropsychiatric disorders due to the relative lack of …

Clinical studies indicate that cannabidiol (CBD), the primary nonaddictive component of
cannabis that interacts with the serotonin (5-HT) 1A receptor, may possess analgesic and …

Over the past years, several lines of evidence support a therapeutic potential of Cannabis
derivatives and in particular phytocannabinoids. Δ 9-THC and cannabidiol (CBD) are the …